MVA vaccine
First Claim
Patent Images
1. A kit of parts comprising the following components:
- a) a first component comprising one or more foreign proteins or a nucleic acid encoding same or functional parts thereof, which functional parts contain one or more substitutions, insertions and/or deletions when compared to the wild type protein whilst having the same function as the wild type protein; and
b) a second component comprising a recombinant Modified Vaccinia Virus Ankara (MVA), which carries a nucleic acid sequence coding for a fusion protein comprising;
Ubiquitin or a functional part thereof, which functional part contains one or more substitutions, insertions and/or deletions when compared to the wild type protein whilst having the same function as the wild type protein; and
one or more foreign proteins, i.e. one or more proteins not naturally present as a part of MVA or functional parts thereof, which functional part contains one or more substitutions, insertions and/or deletions when compared to the wild type protein whilst having the same function as the wild type protein;
wherein the first and second components optionally further comprise a pharmaceutically acceptable carrier.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to a recombinant MVA, which carries a nucleic acid sequence coding for a fusion protein. The present invention is further directed to a kit of parts containing said recombinant MVA as well as to a method for enhancing T cell responses in a mammal.
-
Citations
19 Claims
-
1. A kit of parts comprising the following components:
-
a) a first component comprising one or more foreign proteins or a nucleic acid encoding same or functional parts thereof, which functional parts contain one or more substitutions, insertions and/or deletions when compared to the wild type protein whilst having the same function as the wild type protein; and
b) a second component comprising a recombinant Modified Vaccinia Virus Ankara (MVA), which carries a nucleic acid sequence coding for a fusion protein comprising;
Ubiquitin or a functional part thereof, which functional part contains one or more substitutions, insertions and/or deletions when compared to the wild type protein whilst having the same function as the wild type protein; and
one or more foreign proteins, i.e. one or more proteins not naturally present as a part of MVA or functional parts thereof, which functional part contains one or more substitutions, insertions and/or deletions when compared to the wild type protein whilst having the same function as the wild type protein;
wherein the first and second components optionally further comprise a pharmaceutically acceptable carrier. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
-
19. Use of a recombinant MVA, which carries a nucleic acid sequence coding for a fusion protein comprising:
-
Ubiquitin or a functional part thereof, which functional parts contain one or more substitutions, insertions and/or deletions when compared to the wild type protein whilst having the same function as the wild type protein; and
one or more foreign proteins, i.e. one or more proteins not naturally present as a part of MVA or a functional part thereof, which functional part contains one or more substitutions, insertions and/or deletions when compared to the wild type protein whilst having the same function as the wild type protein, in anti-cancer therapy or in the prevention of infectious diseases as a boosting agent in prime-boost vaccinations.
-
Specification